ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2353

Evaluation Of An Irreversible Dual Target Inhibitor (AC0025) Of Bruton’s Tryosine Kinase and Janus Kinase 3 As a Therapeutic Agent For Rheumatoid Arthritis

Xiao Xu, Long Mao, Biao Xi, Xiaoying Zhang, Che Fang, Jia Liu and Wanhong Xu, ACEA Biosciences Inc., San Diego, CA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: BTK, Janus kinase (JAK) and treatment

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy III

Session Type: Abstract Submissions (ACR)

Background/Purpose: Bruton’s Tryosine Kinase (BTK) and Janus Kinase 3 (JAK3) are intimately involved in the signaling pathways regulating B cell and T cell functions. Perturbing either pathway leads to immune disorders and diseases such as rheumatoid arthritis (RA).  The purpose of the study is to develop a small molecule inhibitor targeting BTK and JAK3

Methods: A novel small molecular inhibitor (AC0025) was rationally designed to selectively target BTK and JAK3 using computer-aided design. The inhibitory activity and selectivity were evaluated at enzymatic, molecular and cellular levels, and in rat CIA animal models. The pharmacological properties and safety were evaluated both in vitro AMEDT assays and in PK/PD/TOX animal models

Results: AC0025 inhibited BTK and JAK3 enzyme activity with IC50values of 0.9 nM for BTK and 0.1 nM for JAK3. AC0025 does not inhibit other JAK family members including JAK1 and JAK2 with the IC50 values of 10.5 µM and 2.16 µM, respectively. AC0025 covalently binds to Cys481 in BTK and Cys909 in JAK3 resulting in irreversible blockage of the ATP binding site of both kinases, and therefore silences BTK and JAK3 activities. The inhibitory potency and selectivity of AC0025 were further evaluated and confirmed in the cell lines either stably expressing BTK and JAK3, or activated by cytokines. In rat collagen-induced arthritis (CIA) model, AC0025 significantly reduced paw edema and the disease severity by oral administration. Pharmacologic properties of AC0025 as a therapeutic agent for RA were assessed using in vitro ADMET assays and PK/PD/Tox animal models.

Conclusion: AC0025 as a novel irreversible dual target inhibitor showed potent inhibitory activities against BTK and JAK3 and further studies to develop AC0025 as a therapeutic agent for RA are warranted.


Disclosure:

X. Xu,

ACEA Biosciences,

3;

L. Mao,

ACEA Biosciences Inc.,

3;

B. Xi,

ACEA Biosciences Inc.,

3;

X. Zhang,

ACEA Biosciences Inc.,

3;

C. Fang,

ACEA Biosciences Inc.,

3;

J. Liu,

ACEA Biosciences Inc.,

3;

W. Xu,

ACEA Biosciences Inc.,

3.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-an-irreversible-dual-target-inhibitor-ac0025-of-brutons-tryosine-kinase-and-janus-kinase-3-as-a-therapeutic-agent-for-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology